New hope for NF2: experimental drug aims to shrink tumors and save hearing
NCT ID NCT07131722
First seen Jan 26, 2026 · Last updated May 12, 2026 · Updated 11 times
Summary
This early-stage trial tests a daily drug called PRG-N-01 in 25 adults with neurofibromatosis type II (NF2), a genetic condition that causes non-cancerous tumors on nerves, often leading to hearing loss. The study aims to find the safest and most effective dose, and to see if the drug can shrink tumors and improve quality of life, including hearing. Participants will take the drug for 96 weeks and have regular clinic visits for monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE II are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.